Literature DB >> 16912303

Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Ianko D Iankov1, Manoj Pandey, Mary Harvey, Guy E Griesmann, Mark J Federspiel, Stephen J Russell.   

Abstract

Antibodies to viral surface glycoproteins play a crucial role in immunity to measles by blocking both virus attachment and subsequent fusion with the host cell membrane. Here, we demonstrate that certain immunoglobulin G (IgG) antibodies can also enhance the entry of measles virus (MV) into monocytes and macrophages. Antibody-dependent enhancement of infectivity was observed in mouse and human macrophages using virions opsonized by a murine monoclonal antibody against the MV hemagglutinin (H) glycoprotein, polyclonal mouse anti-MV IgG, or diluted measles-immune human sera. Neither H-specific Fab fragments nor H-specific IgM could enhance MV entry in monocytes or macrophages, indicating involvement of a Fc gamma receptor (FcgammaR)-mediated mechanism. Preincubation with an anti-fusion protein (anti-F) monoclonal antibody or a fusion-inhibitory peptide blocked infection, indicating that a functional F protein was required for viral internalization. Classical complement pathway activation did not promote infection through complement receptors and inhibited anti-H IgG-mediated enhancement. In vivo, antibody-enhanced infection allowed MV to overcome a highly protective systemic immune response in preimmunized IfnarKo-Ge46 transgenic mice. These data demonstrate a previously unidentified mechanism that may contribute to morbillivirus pathogenesis where H-specific IgG antibodies promote the spread of MV infection among FcgammaR-expressing host cells. The findings point to a new model for the pathogenesis of atypical MV infection observed after immunization with formalin-inactivated MV vaccine and underscore the importance of the anti-F response after vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912303      PMCID: PMC1563851          DOI: 10.1128/JVI.00593-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.

Authors:  Giorgio Trinchieri; Stefan Pflanz; Robert A Kastelein
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

2.  Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus.

Authors:  E Norrby; G Enders-Ruckle; V Meulen
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

3.  High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.

Authors:  Bambi D Anderson; Takafumi Nakamura; Stephen J Russell; Kah-Whye Peng
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

Review 4.  Measles: immune suppression and immune responses.

Authors:  William J Moss; Martin O Ota; Diane E Griffin
Journal:  Int J Biochem Cell Biol       Date:  2004-08       Impact factor: 5.085

5.  Measles vaccines and the potential for worldwide eradication of measles.

Authors:  H Cody Meissner; Peter M Strebel; Walter A Orenstein
Journal:  Pediatrics       Date:  2004-10       Impact factor: 7.124

6.  Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines.

Authors:  V A Fulginiti; J J Eller; A W Downie; C H Kempe
Journal:  JAMA       Date:  1967-12-18       Impact factor: 56.272

Review 7.  Human antibody-Fc receptor interactions illuminated by crystal structures.

Authors:  Jenny M Woof; Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

8.  Antibody-dependent enhancement of Ebola virus infection.

Authors:  Ayato Takada; Heinz Feldmann; Thomas G Ksiazek; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 9.  Measles virus 1998-2002: progress and controversy.

Authors:  Glenn F Rall
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

10.  Cell surface activation of the alternative complement pathway by the fusion protein of measles virus.

Authors:  Patricia Devaux; Dale Christiansen; Sébastien Plumet; Denis Gerlier
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

View more
  28 in total

1.  Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.

Authors:  Ianko D Iankov; Iana H Haralambieva; Evanthia Galanis
Journal:  Vaccine       Date:  2010-12-21       Impact factor: 3.641

Review 2.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

3.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 4.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

5.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

Review 6.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

7.  Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission.

Authors:  Asuka Nanbo; Haruna Terada; Kunihiro Kachi; Kenzo Takada; Tadashi Matsuda
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

8.  Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.

Authors:  Atsushi Yamanaka; Saori Kosugi; Eiji Konishi
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

Review 9.  Dengue virus pathogenesis: an integrated view.

Authors:  Byron E E Martina; Penelope Koraka; Albert D M E Osterhaus
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  Converting tumor-specific markers into reporters of oncolytic virus infection.

Authors:  Ianko D Iankov; Matthew L Hillestad; Allan B Dietz; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.